Business
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
NEW BRUNSWICK, N.J., January 09, 2026--Johnson & Johnson (NYSE: JNJ) (the "Company"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.
About this update from Johnson & Johnson
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2404,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/4507ad9afe8e247ac161b41a52066c55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KrQHDHsQa.NxiRPQPiN51g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg5O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/4507ad9afe8e247ac161b41a52066c55","width":960,"height":89},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/yUN.8T6nuEyNp6TjmYOJ8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0yMjQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4507ad9afe8e247ac161b41a52066c55","width":1200,"height":112}},"lazy":false},{"type":"text","content":"Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted rates","length":108,"tagName":"p"},{"type":"text","content":"Agreement provides Johnson & Johnson pharmaceutical products an exemption from U.S. tariffs","length":95,"tagName":"p"},{"type":"text","content":"Company announces two new additional manufacturing facilities to be built in North Carolina and Pennsylvania; continues to deliver on $55 billion U.S. investment","length":161,"tagName":"p"},{"type":"text","content":"NEW BRUNSWICK, N.J., January 09, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the "Company"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.","length":492,"tagName":"p"},{"type":"text","content":""Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation."","length":532,"...